Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris.
In patients with myocardial infarction, thrombolytic therapy induces a paradoxical activation of the hemostatic mechanism. In patients with unstable angina, the effect of thrombolysis on the coagulation cascade is unknown. We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A in consecutive patients with unstable angina randomized to receive placebo alone (n = 23), streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion (n = 21), or streptokinase 250,000 over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours (n = 20). All the patients received intravenous heparin for 72 hours. The plasma levels of the different markers were measured at baseline, 90 minutes, 24 hours, and 48 hours after the start of therapy. The median baseline plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A were similar in the three treatment groups. In comparison with placebo, an increase in plasma prothrombin fragment 1 + 2 and fibrinopeptide A, was observed after 90 minutes in the two groups receiving thrombolysis. After 24 and 48 hours, the prothrombin fragment 1 + 2 levels remained significantly higher only in the patients receiving the 48-hour streptokinase infusion. In patients with unstable angina, thrombolytic therapy induces an activation of the hemostatic mechanism, despite concomitant heparin administration; in those receiving a prolonged streptokinase infusion, the activation of coagulation persists for as long as the drug is administered.
Merlini
P A
PA
2nd Division of Cardiology, Ca'Granda Niguarda Hospital, Milan, Italy.
Ardissino
D
D
Bauer
K A
KA
Oltrona
L
L
Spinola
A
A
Diotallevi
P
P
Rosenberg
R D
RD
Mannucci
P M
PM
D000368:Aged; D000789:Angina, Unstable / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005344:Fibrinopeptide A / Q000032:analysis*; D006487:Hemostasis / Q000502:physiology*; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis*; D011446:Prospective Studies; D011516:Prothrombin / Q000032:analysis*; D012307:Risk Factors; D013300:Streptokinase / Q000494:pharmacology* / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C045879:prothrombin fragment 1.2; D005344:Fibrinopeptide A; D011516:Prothrombin; D006493:Heparin; D013300:Streptokinase